Effect of P2Y12 inhibitors on inflammation and immunity

View Full Paper

Ask AI

Bookmark

Population

Patients with acute coronary syndromes (ACS)

Design

Review

Discussion

Hypothesis-generating for ticagrelor in sepsis; leaves open clinical adoption pending randomized trials.

Population

Patients with acute coronary syndromes (ACS)

Intervention

P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor)

Outcome

Inflammation and immune responses (platelet-related mediators of inflammation, systemic inflammation markers)surrogate

P2Y12 inhibitors exhibit anti-inflammatory and immune-modulating effects beyond their antithrombotic properties, warranting further investigation.

A 2015 study studied this question.

View Full Paper

Ask AI

Bookmark